News

TAGCyx secured a grant funding from ‘Support Program for Orphan drug prior to the Designation’ of Japan Agency for Medical Research and Development (AMED).

The grant provided by AMED will support ‘Development of a therapeutic agent for treatment of Hunner-type interstitial cystitis (TAGX-0003)’.

Interstitial cystitis (IC) refers to a symptom syndrome complex characterized by persistent pain perceived being related to the urinary bladder in conjunction with urinary frequency and/or urgency. Hunner-type IC (HIC) is a rare intractable disease and diagnosed by the cystoscopic finding of inflammatory lesion known as Hunner lesions. To date, there are no satisfactory treatments for HIC except only symptomatic therapy. It has been established that HIC is caused as a consequence of immune abnormality based on recent research and the patients suffered from HIC often develop autoimmune diseases. IFN-g is known to play a central role in the etiology of HIC like other autoimmune diseases.

TAGCyx are developing TAGX-0003, an anti-IFN- g aptamer, which has high affinity and signal inhibitory activity against IFN- g. TAGX-0003 has been already confirmed possessing a prominent efficacy in a mouse model of HIC, therefore TAGCyx believe that TAGX-0003 will provide a radical cure for HIC patients based on the etiology of HIC.

TAGCyx will advance the preclinical development of TAGX-0003, supported by AMED grant. Additional pharmacological studies, pharmacokinetics studies for PK/PD evaluation, GLP toxicity and safety pharmacology studies, parallel with process development of large-scale synthesis for GMP manufacturing are scheduled under the grant support. For accelerating the preclinical development, Dr. Yoshiyuki Akiyama (Department of Urology, The University of Tokyo Hospital) will advise to this project from a clinical point of view.

AMED website

https://www.amed.go.jp/en/program/list/11/02/001_03-01.html

 

TAGCyx Biotechnologies Inc.

TAGCyx is a research-based company based in Tokyo (Japan). TAGCyx’s scientific team has established its proprietary Xenoligo® technology platform, an innovative drug discovery system using SELEX with a proprietary expanded genetic alphabet, allowing high functional oligonucleotide drug discovery. Xenoligo® platform utilizes genetic alphabet expansion by unnatural base-pairs to generate customized nucleic acid suited for therapeutic applications.

 

TAGCyx website

http://tagcyx.com/en/

Technology

http://tagcyx.com/en/tech-info

Prof. Masanori Matsumoto at Department of Blood Transfusion Medicine, Nara Medical University will give a lecture on the collaboration project at a symposium of The 83rd Annual Meeting of Japanese Society of Hematology (JSH) (September 23-25, virtual)

Symposium 11: ‘New Drug Modalities for the Treatment of Hemostatic and Thrombotic Disorders’

Title: ‘Development of novel aptamer blocking the interaction between VWF A1 domain and platelet GP Ib for the treatment of arterial thrombosis’

http://www.jshem.or.jp/83/

Monasterium laboratory and TAGCyx will present the results of Alopecia Areata project at 2021 European Society for Dermatological Research (ESDR) Annual Meeting (September 22-25, virtual, poster presentation)

Exploring the potential of the novel IFNγ aptamer TAGX-0003 as a treatment for alopecia areata in pre-clinical models

Markus Fehrholz1*, Kaori Harada2*, Ilaria Piccini1, Amos Gilhar3, Susumu Muto2**, Marta Bertolini1**

*and**Both authors contributed equally as first authors and corresponding authors to this work, respectively.

1Monasterium Laboratory, Münster, Germany

2TAGCyx Biotechnologies Inc, Tokyo, Japan

3Technion-Israel Institute of Technology, Haifa, Israel

 

2021 European Society for Dermatological Research (ESDR) Annual Meeting (virtual)

https://esdrmeeting.org/

Results of collaboration project with Prof. Sakamoto Lab (Chiba Institute Technology) will be presented at 22nd International Society of Magnetic Resonance Conference, the 9th Asia-Pacific NMR Symposium, the 60th Annual Meeting of the Nuclear Magnetic Resonance Society of Japan (2021), and the 60th Annual Meeting of the Society of Electron Spin Science and Technology

Results of joint research with Prof. Taiichi Sakamoto, Chiba Institute Technology on the recognition mechanism of Xenoligo® against target proteins based on the structural analysis will be presented in a poster at 22nd International Society of Magnetic Resonance Conference, the 9th Asia-Pacific NMR Symposium, the 60th Annual Meeting of the Nuclear Magnetic Resonance Society of Japan (2021), and the 60th Annual Meeting of the Society of Electron Spin Science and Technology (online), which will be held on the 22nd to 27th of August.

 

August 24, 2021, 8:40〜10:40

Session of Solution NMR: Biological Applications

 

Poster number: P1-2-16

NMR Analysis of Interaction between an ssDNA Aptamer Containing Artificial Base Ds and VEGF165

○Tomomi Nagahama, Tatsuhiko Someya, Susumu Muto, Taiichi Sakamoto

 

Details is obtained here;

https://www.ismar-apnmr2021.org/program.html

https://www.ismar-apnmr2021.org/files/ISMAR-APNMR2021_presentations.pdf